rhIGF-I
Somatomedin-C Lyophilized. Recombinant, human insulin-like growth factor-I (70 amino acids) expressed in E. coli. Has about 40% homology to insulin and produces metabolic effects similar to insulin. Acts as an important local regulator of bone formation. Increases bone formation and bone resorption. Also inhibits etoposide-induced apoptosis in BALB/c 3T3 cells. Stimulates the activity of protein tyrosine kinases in both normal and diethylstilbestrol-treated hamster kidneys. Primarily involved in response of cells to growth hormones. Biological activity: ED50 = 0.3-1.5 ng/ml as measured in a cell proliferation assay with MCF-7 human breast carcinoma cells.. Purity: ≥97% by SDS-PAGE. Contaminants: Endotoxin: ≤1 EU/µg IGF-I. RTECS NM8905000, CAS 67763-96-6. Merck Index: 14, 4986
Ref.: Stabnov, L., et al. 2002. Bone 30, 909. Devireddy, L.R., et al. 2001. Science 293, 829. Chen, C.W., and Ray, D. 1995. Carcinogenesis 16, 1339. Sell, C., et al. 1995. Cancer Res. 55, 303. Amarani, S., et al. 1993. J. Bone Min. Res. 8, 157. Mohan, S. 1993. Growth Regul. 3, 67. Lowe, W.L. 1991. In Insulin-Like Growth Factors: Molecular and Cellular Aspects (LeRoith, D., ed.) CRC Press Inc. Boca Raton, FL. p. 49. Rudd, B.T. 1991. Ann. Clin. Biochem. 28, 542. Schofield, P.N. 1991. Acta Paediatr. Scand. 372, 83. Werner, H., et al. 1991. In Molecular Biology and Physiology of Insulin and Insulin-Like Growth Factors (Raizada, M.K., and LeRoith, D., eds.) Plenum, NY. p. 263. Humbel, R.E. 1984. In Hormonal Proteins and Peptides (Jin Li, C.H., ed.) Academic, NY. Vol. 12, p. 57. |
